Evidence map›Paper›PMID 42771543›Full record

ReviewOncoimmunology2026

IL-15 trans-presentation at the innate-adaptive interface: mechanisms and translation in cancer immunotherapy.

Corey Keith Goldman

Abstract readReview
In one paragraph

Review in Oncoimmunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Corey Keith GoldmanNYU Langone Health/MedAlliance Medical Health Services, New York, NY, United States.ORCID 0009-0008-3386-8224

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Durable antitumor immunity requires innate activation, antigen presentation, lymphocyte priming, trafficking, and effector function. In immunologically cold tumors, deficient dendritic-cell and natural killer (NK)-cell activation limits the transition from tumor-antigen recognition to CD8 T-cell immunity. Interleukin-15 (IL-15) is a member of the common gamma-chain cytokine family with a distinctive receptor-delivery system at this innate-adaptive interface. In native trans-presentation, IL-15 is stabilized by IL-15 receptor alpha (IL-15Rα) on an antigen-presenting cell and presented to CD122/CD132 on an apposed NK or memory CD8 T cell. This contact-dependent arrangement supports NK-cell homeostasis, memory CD8 T-cell maintenance, and spatially restricted signaling while avoiding the CD25-dependent regulatory T-cell preference of IL-2. IL-12, IL-15, and IL-18 can generate cytokine-induced memory-like NK cells with enhanced recall. These programs are constrained by intrinsic CISH feedback and by tumor-associated TGF-

Indexed as

Antigen PresentationImmunity, InnateImmunotherapyInterleukin-15NeoplasmsAdaptive ImmunityAnimalsCD8-Positive T-LymphocytesHumansImmunologic MemoryInterleukin-15 Receptor alpha SubunitKiller Cells, NaturalReceptors, Interleukin-15IL15 protein, humanInterleukin-15Interleukin-15 Receptor alpha SubunitReceptors, Interleukin-15cancer immunotherapycytokine-induced memory-like natural killer cellsIL-15memory CD8 T cellsN-803natural killer cellstrained immunitytrans-presentationtumor microenvironment

Identifiers

PMID42771543
PMCPMC13613925

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.